+612 9045 4394
 
CHECKOUT
Chronically Evolving Viral Hepatitis : Few-Body Systems - C. De Bac

Chronically Evolving Viral Hepatitis

Few-Body Systems

By: C. De Bac (Editor), W. H. Gerlich (Editor), G. Taliani (Editor)

Paperback ISBN: 9783211823507
Number Of Pages: 348

Share This Book:

Paperback

$124.95
or 4 easy payments of $31.24 with Learn more
Ships in 5 to 9 business days

Chronic viral hepatitis is discussed here in a multidisciplinary approach. The editors' goal was to assemble contributions from clinicians, laboratory physicians, epidemiologists, pathologists, and molecular biologists to provide a synopsis of all the important aspects of this disease. A key element in the chronic evolution of viral hepatitis is the persistent coexistence of a cytotoxic immune response and viral gene expression which is discussed in eleven articles on immune pathogenesis. The oncogenicity of hepatitis B virus at the molecular level and of hepatitis C virus at the epidemiological level is discussed in two chapters. The application of PCR for the detection of hepatitis viruses and their variants is a major topic of both practical and theoretical interest. The clinical significance of newly developed serological assays for diagnosis and prevention is discussed in depth by specialists from clinics, transfusion centers and virological laboratories. The therapy of chronic viral hepatitis is still unsatisfactory, but some slow progress is described in several articles. Furthermore, the volume has a special chapter on the often neglected topic of chronic hepatitis in childhood.

Immune pathogenesis of hepatitis Ap. 3
Relapsing hepatitis A in Saimiri monkeys experimentally reinfected with a wild type hepatitis A virus (HAV)p. 5
Immune pathogenesis of hepatitis Bp. 11
T cell recognition of hepatitis B envelope proteinsp. 19
Fine specificity of the human T cell response to hepatitis B virus core antigenp. 23
HBcAg induced T-cell independent anti-HBc production in chronic HBsAg carriersp. 29
Divergent anti-HBc reactivities in HB-immune and chronic HBsAg carriersp. 36
Absence of free core antigen in anti-HBc negative viremic hepatitis B carriersp. 39
Homing of T-lymphocytes in acute and chronic HBV positive inflammatory liver diseasep. 42
Hepatitis B virus specific transcripts in peripheral blood mononuclear cellsp. 46
Detection of transcriptionally active hepatitis B virus DNA in peripheral mononuclear blood cells after infection during immunosuppressive chemotherapy using the polymerase chain reactionp. 50
The hepatitis B virus X protein transactivation of c-fos and c-myc proto-oncogenes is mediated by multiple transcription factorsp. 57
Trans-Activation by hepatitis B virus X protein is mediated via a tumour promotor pathwayp. 63
Truncated pre-S S proteins transactive multiple target sequencesp. 65
Hepatitis C virus and hepatocellular carcinomap. 70
Prevalence of antibodies to hepatitis C virus in patients with hepatocellular carcinoma in Austriap. 76
Variants of hepatitis B virusp. 83
Hepatitis B virus genomic variations in chronic hepatitisp. 86
Replication of molecularly cloned HBcAg negative hepatitis B virus variant in transfected HepG2 cellsp. 90
Lack of pre-C region mutation in woodchuck hepatitis virus from seroconverted woodchucksp. 95
Clinical significance of polymerase chain reaction (PCR) assay in chronic HBV carriersp. 97
PreS antigen expression and anti-preS response in hepatitis B virus infections: relationship to serum HBV-DNA, intrahepatic HBcAg, liver damage and specific T-cell responsep. 105
PCR analysis of HBV infected sera: relationship between preS antigens expression and viral replicationp. 113
Detection of HBV DNA by PCR in serum from an HBsAg negative blood donor implicated in cases of post-transfusion hepatitis Bp. 116
HBc and HBe specificity of monoclonal antibodies against complete and truncated HBc proteins from E. colip. 119
Measurement of anti-HBc IgM levels using the Amerlite anti-HBc IgM assayp. 122
Evaluation of a new enhanced luminescence immunoassay for confirming the presence of HBsAg in human serum or plasmap. 124
Functions of hepatitis B surface proteinsp. 129
Deletion and insertion mutants of HBsAg particlesp. 133
Properties of a recombinant yeast-derived hepatitis B surface antigen containing S. preS2 and preS1 antigenic domainsp. 137
Diverging policies for vaccination against hepatitis Bp. 142
Immunogenicity and safety of a recombinant hepatitis B vaccine produced in mammalian cells and containing the S and the preS2 sequencesp. 147
Kinetics of anti-HBs after hepatitis B vaccination: a comparison of two recombinant and one plasma-derived vaccinesp. 154
Enhanced luminescent assays for hepatitis markers: Assessment of post vaccine responsesp. 156
Comparative molecular biology of flaviviruses and hepatitis C virusp. 163
Hepatitis C viral RNA in serum of patients with chronic non-A, non-B hepatitis: Detection by the polymerase chain reaction using multiple primer setsp. 172
Detection and characterization of hepatitis C virus sequence in the serum of a patient with chronic HCV infectionp. 179
Sequence analysis of PCR amplified hepatitis C virus cDNA from French non-A, non-B hepatitis patientsp. 184
Antigenicity of synthetic peptides derived from C100 protein of hepatitis C virusp. 186
Localization of hepatitis C virus antigen(s) by immunohistochemistry on fixed-embedded liver tissuep. 191
Identification of HCV-associated antigen(s) in hepatocytesp. 196
Hepatitis C virus (HCV) and autoimmune liver diseasesp. 201
Antibodies to hepatitis C virus in primary biliary cirrhosisp. 205
Prevalence of antibodies against hepatitis C virus in primary biliary cirrhosis and autoimmune chronic hepatitisp. 210
HCV infection and chronic active hepatitis in alcoholicsp. 212
Hepatitis C virus infection in patients with idiopathic hemochromatosis (IH) and porphyria cutanea tarda (PCT)p. 215
Diagnostic reagents for hepatitis C virusp. 219
Follow-up of patients with hepatitis non-A. non-B: incidence and persistence of anti-HCV depend on route of transmissionp. 222
Confirmation of anti-HCV EIA reactivities by RIBA and neutralization assay among blood donors and patients with chronic liver disease and hepatocellular carcinomap. 227
Recombinant immunoblot assay for hepatitis C virus antibody in chronic hepatitisp. 232
PCR detection of HCV RNA among French non-A. non-B hepatitis patientsp. 234
HCV and blood transfusionp. 241
Evaluation of anti-HCV positive blood donors identified during routine screeningp. 244
Presence of HCV RNA in serum of asymptomatic blood donors involved in post-transfusion hepatitis (PTH)p. 247
Epidemiology of anti-HCV antibodies in Francep. 249
Assay of antibodies to hepatitis C virus protein C100-3 in blood donors from Northern Germanyp. 253
Chronic viral hepatitis in childrenp. 259
Long-term outcome of chronic type B hepatitis in childhoodp. 263
Hepatitis in children with thalassemia majorp. 265
Hepatitis in pre-school children: prevalent role of cytomegalo-virusp. 268
Repeated course of interferon treatment in chronic hepatitis B in childhoodp. 273
Effect of prednisone priming followed by alfa-interferon in treatment of children with chronic hepatitis B: an interim analysis of a controlled trialp. 277
Association between HLA class 1 antigens and response to interferon therapy in children with chronic HBV hepatitisp. 281
Treatment of chronic viral hepatitis anno 1990p. 287
Induction of autoantibodies during alpha interferon treatment in chronic hepatitis Bp. 291
One course versus two courses of recombinant alpha interferon in chronic C hepatitisp. 294
Interferon therapy of cryptogenic chronic active liver disease and its relationship to anti-HCVp. 299
Interferon alpha 2-b therapy of HCV and NonBNonC chronic hepatitisp. 304
Long-term effects of recombinant leukocyte alpha interferon in the treatment of chronic delta hepatitisp. 306
Liver transplantation and hepatitis virusesp. 311
Prevalence of antibody to hepatitis C virus in acute non-A, non-B hepatitis in patients from different epidemiological categoriesp. 319
Prevalence of anti-HCV antibodies in patients with acute nonA-nonB viral hepatitisp. 321
Antibody to hepatitis C virus in acute, self-limited, type B hepatitisp. 323
HCV infection in HBsAg positive chronic liver diseasep. 325
Prevalence of antibody to hepatitis C virus in chronic HBsAg carriersp. 327
HBV and HCV infection in i.v. drug addicts; coinfection with HIVp. 329
HCV and HIV infection among intravenous drug abusers in Eastern Sicilyp. 333
Anti-hepatitis C antibody prevalence among intravenous drug addicts in the Catanzaro areap. 335
Hepatitis C virus (HCV) infection in the Piacenza dialysis centerp. 337
Prevalence of hepatitis C virus (HCV) antibodies in hemodialysis patientsp. 339
Preliminary investigation on intrafamilial spread of hepatitis C virus (HCV)p. 343
Involved factors in the intrafamilial spread of hepatitis C virusp. 345
Prevalence of anti-HCV in two Tanzanian villagesp. 347
Table of Contents provided by Blackwell. All Rights Reserved.

ISBN: 9783211823507
ISBN-10: 3211823506
Series: Few-Body Systems
Audience: General
Format: Paperback
Language: English
Number Of Pages: 348
Publisher: SPRINGER VERLAG GMBH
Country of Publication: AT
Dimensions (cm): 27.94 x 20.96  x 1.91
Weight (kg): 0.82